DoMore Diagnostics vs Valar Labs
Both read a routine stained slide and predict what happens next, which is a different and harder claim than detecting what is already there. DoMore predicts outcome in stage two and three colorectal cancer, aimed squarely at the adjuvant chemotherapy decision where staging alone leaves clinicians guessing. Valar predicts treatment response and prognosis from the same kind of slide, deepest in non muscle invasive bladder cancer with two products covering different decisions in that pathway, and it holds the strongest evidence base of the prognostic pathology vendors here including multi centre validation across four continents. Neither is a cleared device; both are laboratory developed tests, so no regulator has reviewed the performance. For a colorectal service DoMore is the relevant one, for bladder Valar, and in both cases the validation cohort is the thing to interrogate.
- The evidence base is the strongest among the prognostic pathology vendors here and independent in the ways that matter, including multi centre validation across an international cohort spanning four continents.
- Depth in non muscle invasive bladder cancer is real, with two distinct products addressing different decisions in that pathway rather than one general prognostic score.
- There is nothing to deploy: a practice sends existing specimens and receives results, which removes the integration project entirely.
- The prognostic signal is extracted from standard stained slides in colorectal cancer, targeting the stage II and III decision where adjuvant treatment is genuinely uncertain and current staging under performs.
- Focus is the argument: one cancer, one decision, validated for it, rather than a platform claim spanning tumour types.
- For a colorectal service the question of who benefits from adjuvant chemotherapy is the highest value uncertainty in the pathway, and that is what this test addresses.
Side by Side
| Axis | D DoMore Diagnostics |
V Valar Labs |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are laboratory developed tests rather than cleared devices, which is a different regulatory route and means no regulator has reviewed the performance claims; ask both for the validation cohorts and how closely they match your own population. Neither publishes pricing, though the laboratory developed test model implies per test economics an oncology practice will recognise. Neither publishes a security attestation.
The shared and largely unaddressed exposure is that prognostic models trained on slides from particular laboratories inherit those laboratories' staining and scanning characteristics, so performance can degrade on tissue prepared elsewhere without any visible signal.